Scarica l'app Stockscreener
42.99
1.01%
-0.44
Dopo l'orario di chiusura:
42.99
Livanova Plc Borsa (LIVN) Ultime notizie
Principal Financial Group Inc. Purchases 3,668 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
Jefferies Reiterates a Buy Rating on LivaNova PLC (LIVN) With a $79 PT - Insider Monkey
10 Undervalued Medical Device Stocks to Buy Now - Insider Monkey
How LivaNova PLC stock performs during market volatilityStable Stocks With High Yield - Newser
Vagus Nerve Stimulators Market Exclusive Report with Detailed - openPR.com
LivaNova to Announce Second-Quarter 2025 Results | LIVN Stock Ne - GuruFocus
LivaNova to Announce Second-Quarter 2025 Results - The Joplin Globe
LivaNova: The Sell-Off Is Excessive Here (NASDAQ:LIVN) - Seeking Alpha
Here's Why LivaNova (NASDAQ:LIVN) Can Manage Its Debt Responsibly - 富途牛牛
Trading (LIVN) With Integrated Risk Controls - news.stocktradersdaily.com
LivaNova PLC(NasdaqGS: LIVN) dropped from Russell 2000 Growth Index - MarketScreener
LivaNova PLC(NasdaqGS: LIVN) dropped from Russell 2000 Growth-Defensive Index - MarketScreener
Are Options Traders Betting on a Big Move in LivaNova Stock? - Nasdaq
Latest Developments and Regulatory Approvals - openPR.com
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, - openPR.com
Global Neuromodulation Market to grow at a CAGR of 8.95% by 2030, Evaluates DelveInsight | Medtronic, Abbott, Boston Scientific Corp, LivaNova, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc - Barchart.com
Global Neurostimulation Devices Market to grow at a CAGR - openPR.com
(LIVN) Investment Report - news.stocktradersdaily.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com Nigeria
Wearable Cardioverter Defibrillators (WCD) Market Growth | - openPR.com
LivaNova Shareholders Approve New Incentive Plans - Investing.com
LivaNova Shareholders Approve New Incentive Plans By Investing.com - Investing.com Canada
LivaNova Shareholders Approve Key Incentive Plans at AGM - TipRanks
Livanova petitions CMS to drop CED mandate for VNS for depression - BioWorld MedTech
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com South Africa
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com South Africa
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com India
LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Artificial Heart Lung Machines Market Projected to Witness - openPR.com
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Th - GuruFocus
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus
LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider
VNS therapy shows sustained seizure reduction in study - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - Business Wire
LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider
LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa
LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice
Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus
LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy - GuruFocus
LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression | LIVN Stock News - GuruFocus
0.59%
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):